

07-06-04

5th 1647

Please place a plus sign (+) inside this box ☐

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/028,410
		Filing Date	December 19, 2001
		First Named Inventor	Yves DUBAQUIE et al.
		Group/Art Unit	1647
		Examiner Name	BUNNER, Bridget E.
Total Number of Pages in This Submission	7	Attorney Docket Number	39766-0131 R1-1D1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> Information Disclosure Statement with PTO-1449 (4 sheets) and 55 references	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): stamped return postcard
Remarks		
AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	Leslie A. Mooi, Reg. No. 37,047, HELLER EHRMAN WHITE & McAULIFFE LLP		
Signature	<i>Leslie Mooi</i>		
Date	July 2, 2004	Customer Number:	25213

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450			
Express Mail Label EL 976 544 537 US			
Typed or printed name	Jan Huss	Date	July 2, 2004
Signature	<i>Jan Huss</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Via Express Mail Label EL 976 544 537 US on July 2, 2004

PATENT

Attorney Docket No. 39766-0131 R1-1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: BUNNER, Bridget E.
)	
Yves DUBAQUIE, et al.)	Art Unit: 1647
)	
Application No.: 10/028,410)	Confirmation No. 4233
)	
Filed: December 19, 2001)	Attorney's Docket No. 39766-0131 R1-1D1
)	
Title IGF AND INSULIN VARIANTS)	Customer No. 25213
)	

SUPPLEMENTARY

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39766-0131 R1-1D1).

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: July 2, 2004


By: Leslie Mooi
Leslie A. Mooi, Reg. No. 37,047

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213


US Appl. No. 10/028,410
Attorney Docket No. 39766-0131 R1-1D1

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.		SERIAL NO.		
			39766-0131 R1-1D1		10/028,410		
			APPLICANT Yves DUBAQUIE et al.				
			FILING DATE December 19, 2001		GROUP: 1647		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,473,049	12-1995	Obermeier et al				
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/20023	4-2000	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	WO 00/23469	4-2000	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	WO 00/69901	11-2000	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	WO 89/08667	9-1989	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	WO 89/09268	10-1989	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	WO 89/09792	10-1989	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	EP 128733	12-1984	EP			<input type="checkbox"/>	<input type="checkbox"/>
	EP 230869	8-1987	EP			<input type="checkbox"/>	<input type="checkbox"/>
	EP 288451	10-1988	EP			<input type="checkbox"/>	<input type="checkbox"/>
	EP 294021	12-1988	EP			<input type="checkbox"/>	<input type="checkbox"/>
	EP 369943	5-1990	EP			<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Barnett and Owens, "Insulin analogues" <u>Lancet</u> 349 (9044): 47-51 (Jan. 4, 1997)							
Bass et al., "Hormone Phage: An Enrichment Method for variant proteins with altered binding properties", <u>Proteins : Structure, Function, and Genetics</u> 8 (4): 309-314 (1990)							
Baxter & Martin, "Binding Proteins For Insulin-Like Growth Factors In Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins" <u>Biochem & Biophys Res. Comm.</u> 147(1):408-415 (1987)							
Baxter, R., "The Insulin-Like Growth Factors and Their Binding Proteins" <u>Comp. Biochem. Physiol.</u> 91B(2): 229-235 (1988)							
Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)" <u>EMBO Journal</u> 8: 2497-2502 (1989)							
EXAMINER			DATE CONSIDERED				


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT  TO-1449	ATTY. DOCKET NO. 39766-0131 R1-1D1	SERIAL NO. 10/028,410
	APPLICANT Yves DUBAQUIE et al.	
	FILING DATE December 19, 2001	GROUP: 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Bornfeldt et al., "Binding and biological effects of insulin, insulin analogues and insulin-like growth factor in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities" <u>Diabetologia</u> 34(5): 307-313 (May 1991)	
	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions" <u>Science</u> 247: 1306-1310 (1990)	
	Brange et al., "Designing insulin for diabetes therapy by protein engineering" <u>Current Opinion in Structural Biology</u> 1: 934-940 (1991)	
	Brange et al., "Monomeric insulins obtained by protein engineering and their medical implications" <u>Nature</u> 333 (6174) : 679-682 (Jun 16, 1988)	
	Brange, J., "Insulin Preparations" <u>Galenics of Insulin, The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations</u> , New York: Springer-Verlag, pps. 17-40 (1987)	
	Brenner, S.E., "Errors in Genome Annotation" <u>Trends in Genetics</u> 15: 132-133 (1999)	
	Brewer et al., "Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein" <u>Biochem & Biophys. Res. Comm.</u> 152(3): 1289-1297 (1988)	
	Brinkman et al., "Isolation and Characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)" <u>The EMBO J.</u> 7:2417-2423 (1988)	
	Cara et al., "An insulin-like growth factor I/insulin hybrid exhibiting high potency for interaction with the type I insulin-like growth factor and insulin receptors of placental plasma membranes" <u>Journal of Biological Chemistry</u> 265 (29):17820-17825 (Oct 15, 1990)	
	Chang et al., "Single-Step Solubilization and Folding of IGF-1 Aggregates From Escherichia coli" <u>Protein Folding: In Vivo and In Vitro</u> , American Chemical Society, Chapter 14, pps. 178-188 (1993)	
	Clackson et al., "A Hot Spot of Binding Energy in a Hormone-Receptor Interface" <u>Science</u> 267: 383-386 (1995)	
	Cunningham et al., "Engineering Human Prolactin to Bind to the Human Growth Receptor" <u>Science</u> 247:1461-1465 (1990)	
	DiCera, E., "Site-Specific Thermodynamics: Understanding Cooperativity in Molecular Recognition" <u>Chem. Rev.</u> 98: 1563-1591 (1998)	
	DiMarchi et al., "Synthesis of a fast-acting insulin analog based on structural homology with insulin-like growth factor-I" <u>Peptides: Chemistry and Biology</u> (Proceedings of the Twelfth American Peptide Symposium) J.A. Smith and J.E. River, eds., Leiden: ESCOM pps. 26-28 (1992)	
	Dodd et al., "Reversible Adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electrostatic interaction" <u>Pharmaceutical Research</u> 12(1):60-68 (Jan 1995)	
	Drejer, K., "The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake" <u>Diabetes-Metabolism Reviews</u> 8(3): 259-285 (Oct 1992)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449 	ATTY. DOCKET NO. 39766-0131 R1-1D1	SERIAL NO. 10/028,410
	APPLICANT Yves DUBAQUIE et al.	
	FILING DATE December 19, 2001	GROUP: 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Hober et al., "Disulfide Exchange Folding of Insulin-Like Growth Factor I" <u>Biochemistry</u> 31: 1749-1756 (1992)	
	Howey et al., "[Lys(B28), Pro(B29)]-Human Insulin: an Equipotent Analog of Human Insulin with Rapid Onset and Short Duration of Action" <u>Diabetes</u> (Abstract #1688) 40(Suppl 1): 423A (1991)	
	Hua, Qing-Hua et al., "Mini-proinsulin and Mini-IGF-I: Homologous Protein Sequence Encoding Non-homologous Structures" <u>JBM</u> 277:103-118 (1998)	
	Kang et al., "Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, Glu B27; Asp B10, Asp B28) on meal-related plasma glucose excursions in type I diabetic subjects: <u>Diabetes Care</u> 14(7): 571-577 (Jul 1991)	
	Kelley et al., "Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding" <u>Biochemistry</u> 34(33): 10383-10392 (1995)	
	Kunkel et al., "Efficient site-directed mutagenesis using uracil-containing DNA" <u>Methods in Enzymology</u> 204: 125-139 (1991)	
	Lassalle et al., "ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines" <u>Journal of Biological Chemistry</u> 271: 20458-20464 (1996)	
	Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression" <u>Nature</u> 330:537-543 (1987)	
	Lowman et al., "Selecting High-Affinity Binding Proteins by Monovalent Phage Display" <u>Biochemistry</u> 30 (45): 10832-10838 (1991)	
	Lowman et al., "Exchanging Interleukin-8 and Melanoma Growth-stimulating Activity Receptor Binding Specificities" <u>Journal of Biological Chemistry</u> 271(24): 14344-14352 (1996)	
	Lowman et al., "Mutational Analysis and Protein Engineering of Receptor-Binding Determinates in Human Placental Lactogen" <u>Journal of Biological Chemistry</u> 266(17): 10982-10988 (Jun 15, 1991)	
	Martin & Baxter "Insulin-like Growth Factor-Binding Protein from Human Plasma. Purification and Characterization" <u>Journal of Biological Chemistry</u> 261(19): 8754-8760 (1986)	
	Ngo et al., "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox" <u>The Protein Folding Problem and Tertiary Structure Prediction</u> Merz & Le Grand, Boston:Birkhauser, pps. 491-495 (1994)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT 	ATTY. DOCKET NO. 39766-0131 R1-1D1	SERIAL NO. 10/028,410
	APPLICANT Yves DUBAQUIE et al.	
	FILING DATE December 19, 2001	GROUP: 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Oh et al., "Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7 Recombinant human mac25 protein specifically binds IGF-I and -II <u>Journal of Biological Chemistry</u> 271: 30322-30325 (1996)	
	Powell et al, "Characterization of insulin-like growth factor binding protein-3 in chronic renal failure serum" <u>Pediatric Research</u> 33(2):136-143 (Feb 1993)	
	Rinderknecht and Humbel "The Amino Acid Sequence of Human Insulin-Like Growth Factor I and It's Structural Homolgy With Proinsulin" <u>Journal of Biological Chemistry</u> 253(8): 2769-2776 (1978)	
	Sliker and Sundell, "Modifications in the 28-29 position of the insulin B-chain alter binding to the IGF-I receptor with minimal effect on insulin receptor binding" <u>Diabetes</u> (Abstract #670) 40(suppl. 1): 168A (1991)	
	Swisshelm et al., "Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid" <u>Proc. Natl. Acad. Sci.</u> 92: 4472-4476 (1995)	
	Weiss et al., "Heteronuclear 2D NMR studies of an engineered insulin monomer: assignment and characterization of the receptor-binding surface by selective 2H and 13C labeling with application to protein design" <u>Biochemistry</u> 30(30): 7373-7389 (1991)	
	Wolpert et al., "Identification of an insulin analog with enhanced growth effect in aortic smooth muscle cells" <u>Diabetes</u> 39 (Suppl. 1): 140A (1990)	
	Wood et al., "Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein" <u>Molecular Endocrinology</u> 2: 1176-1185 (1988)	
	Yamauchi et al., "Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells" <u>Biochemical Journal</u> 303(Part 2): 591-598 (1994)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SV 2043495 v1
7/2/04 10:32 AM (39766.0131)